相关实验视频

Updated: May 15, 2025

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

由METTL14介导的lncRNA NEAT1通过调节miR-302a-3p/March5轴来促进喘的进展

Yawei Wu¹, Qiuyun Ye¹, Dandan Chen²

¹Department of Pulmonary and Critical Care Medicine, Hainan Affiliated Hospital of Hainan Medical University, China.

International immunopharmacology

|May 13, 2025

概括

长非编码RNA NEAT1 通过抑制细胞和调节 miR-302a-3p/March5 轴促进喘. METTL14增强了NEAT1的表达,这表明NEAT1是潜在的喘生物标志物.

科学领域:

分子生物学分子生物学
免疫学免疫学免疫学
呼吸系统医学呼吸系统医学

背景情况:

喘是一种慢性呼吸道炎症疾病,其特点是呼吸道重塑.
长非编码RNANEAT1在喘中的精确调节机制尚不清楚.
据报道,NEAT1在喘中被上调,但它的上游和下游途径需要阐明.

研究的目的:

研究IncRNA NEAT1在喘发病过程中的作用和功能机制.
探索气道光滑肌细胞 (ASMC) 中涉及NEAT1,微RNA-302a-3p和March5的调节轴.
确定METTL14介导的m6A修饰对NEAT1表达和喘进展的影响.

主要方法:

从喘患者和健康志愿者中分离和转移ASMC.
基因表达分析使用实时定量PCR (qRT-PCR) 和西部涂抹.
通过传输电子显微镜 (TEM) 评估ASMC的扩散,迁移,炎症,ROS水平和髓.
建立喘小鼠模型,以验证体内发现的结果.

主要成果:

在喘患者的ASMC中,IncRNA NEAT1的调节显著上升.
NEAT1的过度表达增强了ASMC的扩散和迁移,促进了炎症,并抑制了线粒.
确定了NEAT1/miR-302a-3p/March5轴作为一个关键的监管途径.
发现METTL14通过m6A修饰来增强NEAT1的表达,加剧了喘病理.
在小鼠模型中,NEAT1的淘汰减轻了喘病理.

结论:

由METTL14介导的NEAT1的m6A修饰通过通过miR-302a-3p/March5轴抑制甲基食来促进喘进展.
lncRNA NEAT1在呼吸道重塑和喘发病过程中发挥着至关重要的作用.
lncRNA NEAT1代表了一个潜在的治疗标和喘的诊断生物标志物.

关键词:

气道改造气道改造气道改造喘喘是一种炎症炎症是一种炎症.在 LncRNA NEAT1 中.线粒细胞衰变 - - 线粒细胞衰变 (mitophagy) 是一种

更多相关视频

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Asthma-I: Introduction

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...